contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-receives-system-order-from-distributor-in-india

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

MedTech World Middle East, taking place from 11 to 13 February https://med-tech.world/news/meet-startups-and-exhibitors-medtech-world-middle-east-dubai-2026/ Sinaptica has its own “booth” in Dubai.

Fresh research with Nexstim’s TMS-EEG. Precision is increasing, and it may open up more opportunities in the future. If anyone on this forum is more familiar with the field, perhaps they could provide a slightly more detailed interpretation of the study for us laypeople. In any case, it’s great that research data on TMS-EEG is starting to emerge this quickly. “These findings have important clinical implications, opening new opportunities for the individualization of therapeutic interventions.” https://www.biorxiv.org/content/10.64898/2026.01.30.702764v1.full.pdf+html

We also have to be prepared for the possibility that Inderes’ forecast hits the mark and there really are exactly zero deals. Sometimes the explanation is very simple and the answer is staring us right in the face when wondering why no diagnostic sales have been announced. The wait feels long with this semi-annual reporting..

The top 100 owners seem to be mainly on the buying side. The largest seller appears to be at rank 94 and is likely the same person who wrote about their reductions on the KL forum. They will soon run out of shares to dump (they had 7,813 left at the turn of the month), and the fire sales will likely be over for a while. I’m certainly waiting for the end of the month and the earnings release with interest. In my opinion, it is now quite clear that Inderes’ analysis is way off once again, as no diagnostic deals have been announced. I think it would be quite surprising if there were zero diagnostic deals in the last quarter, as Inderes has predicted. Along with the earnings release, the first positive result will also be made public, and consequently, the stock will naturally start to attract a new kind of interest.

Agreed. Even though Nexstim’s devices operate in the head area, it doesn’t mean they can perform every treatment that happens in the dome. At least not yet. To avoid this being a complete zero-effort post, I’ll link last month’s top 100 shareholder change statistics. At least Kyösti hasn’t continued selling, and the list of top names doesn’t look too bad otherwise.                   nexstim.com              Nexstim - Nexstimin suurimmat osakkeenomistajat

Surely tumor removal has nothing to do with Nexstim’s device, except perhaps for the need for pre-operative mapping where Nexstim’s device is required? Do you also go and comment on the Tesla stock thread when some “competing” company launches a new version of a forestry machine?

In a way, a Nexstim system could be sold alongside it to perform the mapping first, so that the treatment is easier and safer. That is, after all, a laser used to destroy the tumor.

Nexstim

Press release, Helsinki, 2 February 2026 at 9 AM (EET) Nexstim Receives System Order from Distributor in IndiaNexstim Plc ("Nexstim" or "Company") has received an order for an NBS System 5 through...

Press release, Helsinki, 2 February 2026 at 9 AM (EET)&nbsp;Nexstim Receives System Order from Distributor in IndiaNexstim Plc ("Nexstim" or "Company") has received an order for an NBS System 5 through a distributor in India. The end customer has an earlier generation Nexstim system.Nexstim gained an import license from the Central Drugs Standard Control Organization of the Government of India in October 2024 for the NBS System 5.The NBS System 5 is intended to be used in pre-surgical mapping of the speech and motor cortices of the brain. A separate module, NexSpeech®, is needed for speech mapping purposes. Nexstim also offers a possibility to add a therapy module to the system, allowing it to be used for the treatment of major depression and chronic neuropathic pain. The system ordered includes all these modules.Mikko Karvinen, CEO of Nexstim, comments: “We are proud of the increased global reach of our products, and happy to expand our presence in India. The combined system option enables versatile use of the device, and enable this customer to enjoy the high-quality diagnostics and therapy treatment opportunities offered by our technology.”Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim PlcNexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit&nbsp;<a href="http://www.nexstim.com/">www.nexstim.com</a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/1bfc2d67-4880-4095-9f6f-9792d58e6137/nexstim-plc-press-release-india-order-02022026-final.pdf">Nexstim Plc_Press release_India order_02022026_FINAL.pdf</a></div> </div>